The mission of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the United States Food and Drug Administration (FDA) is to identify, prioritize, sponsor, coordinate, and promote innovative activities — with a special interest in optimizing clinical trials — that will expedite the discovery and development of improved analgesic, anesthetic, addiction, and peripheral neuropathy treatments for the benefit of the public health.
ACTTION is a multi-year, multi-phase initiative that is closely aligned with the FDA's Critical Path Initiative. This public-private partnership has been designed to streamline the discovery and development process for new analgesic, anesthetic, addiction, and peripheral neuropathy medications and to more generally accelerate the development of treatments with improved efficacy and safety.
The key objectives of ACTTION involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders — including, but not limited to, academia, the FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations — with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.
ACTTION is intended to have benefits that are international in scope. To represent the bridges that ACTTION is establishing among its diverse stakeholders, this website is illustrated with watermarks of two bridges that share the distinction of connecting different continents. Directly below is the First Bosphorus Bridge in Istanbul, Turkey, which connects Europe and Asia; on the Contact Us webpage is the Leifur Eiriksson Bridge in Iceland's Reykjanes peninsula, which spans a rift valley between the North American and European continental plates.
February 29, 2016: Upcoming ACTTION Presentations at the American Pain Society
ACTTION Assistant Directors, Jennifer Gewandter, PhD, and Shannon Smith, PhD, will present posters at the annual meeting of the American Pain Society, to be held in Austin, Texas from May 11-14, 2016, that report on ACTTION Working Group projects. Dr. Gewandter will describe the results of a review of cross-over clinical trials of neuropathic and musculoskeletal pain; she will be at the author-attended poster session on Thursday, May 12 from 9:30-11am. Dr. Smith will present the results of a study of patient preferences for pain clinical trial characteristics; she will be at the author-attended poster session on Thursday, May 12 from 3:45-5:15pm. The complete references for these two presentations are:
Gewandter JS, McKeown A, McDermott MP, Hoang K, Iwan K, Kralovic S, Rothstein D, Gilron I, Katz NP, Senn S, Smith SM, Turk DC, Dworkin RH. Reporting of cross-over clinical trials of analgesic treatments for neuropathic and musculoskeletal pain: ACTTION systematic review and recommendations.
Smith SM, Gewandter JS, Kitt R, Markman JD, Vaughan JA, Cowan P, Sadosky A, Tive L, Turk DC, Dworkin RH. Preferences for pain clinical trial characteristics: an ACTTION adaptive choice-based conjoint survey study.
January 4, 2016: ACTTION to Support North American Pain School in Collaboration with IASP
ACTTION is delighted to announce that the Quebec Pain Research Network will present the North American Pain School (NAPS), an educational initiative of IASP, in collaboration with ACTTION. NAPS will be held June 26-30, 2016, at the Hotel Chateau Bromont, Montreal, and ACTTION Associate Director, Dennis Turk, PhD, will be delivering a keynote lecture, "Chronic Pain: Snapshots and Motion Pictures." Additional information and application instructions can be found at http://northamericanpainschool.com.